Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
about
Mechanism by which metformin reduces glucose production in type 2 diabetesMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenaseBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPMetformin monotherapy for type 2 diabetes mellitusMetformin for women who are obese during pregnancy for improving maternal and infant outcomesRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusMetformin monotherapy for type 2 diabetes mellitusAdvances in diabetes for the millennium: drug therapy of type 2 diabetesCurrent understanding of metformin effect on the control of hyperglycemia in diabetesTreatment of prediabetesSerine, glycine and one-carbon units: cancer metabolism in full circleOxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitusCinnamon use in type 2 diabetes: an updated systematic review and meta-analysisMechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetesMetformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent mannerThe Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter TrialMetformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent BiosynthesisEffect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studiesPioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.Vitamin D status and its association with insulin resistance among type 2 diabetics: A case -control study in GhanaMetformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesisThiazolidinediones: a new class of antidiabetic drugs.Current therapeutic options in type 2 diabetes.Oral antihyperglycemic therapy for type 2 diabetes mellitus.The effects of vitamin D supplementation on hepatic dysfunction, vitamin D status, and glycemic control in children and adolescents with vitamin D deficiency and either type 1 or type 2 diabetes mellitusNew directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.Glucose supply and insulin demand dynamics of antidiabetic agents.Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes.Molecular mechanism of insulin resistance in obesity and type 2 diabetes.The glitazones: proceed with caution.Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.Pharmacotherapy of type 2 diabetes mellitus.Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese ratsInsulin sensitiser drugs.Effects of current therapeutic interventions on insulin resistance.Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review.Enhancing insulin action: from chemical elements to thiazolidinediones.
P2860
Q22241286-79944CF5-56E0-44A5-8EFA-0567C267C720Q22251079-7C48B8F1-C64F-4469-AAFB-3E305ECB8EABQ22251081-31B22903-2F80-44D9-BCE5-BD834AC9598FQ24187392-5BEE3D53-25FE-4480-95EA-05491F44BF6AQ24202468-BE25E1AC-84EA-4993-B477-3F865E5346BFQ24235718-F9EEE755-C04F-4662-A7A0-30B35637674BQ24240522-42B6EBD7-5B72-4570-A2F2-A97F916F8D0CQ24246552-ADA162DC-78C6-444D-A815-7F4CAF4909FAQ24547558-97B3DAB2-2021-4567-8ABA-322DADA3AEC8Q26770236-33E612A6-3035-41A3-833B-9EB8B419A258Q26783350-43353347-0FF9-4ECB-993E-E924773313E6Q26828610-3C93A2DC-0A04-4773-9B01-AA8B62983D70Q26829529-0EF19D97-6C56-47E5-A241-2219D67484E3Q27022291-BD1BB90D-2E57-4526-BC11-62A1583D2C50Q28193039-AED1F1A0-51CE-4598-8560-E5C07617B02BQ28539904-D698F5F9-7413-4FEB-A970-F78609B2350DQ28548552-765DF0E1-CDAB-4D7F-964B-1BF90CCD9C9DQ28551227-CDAD39FE-53ED-4AE2-8F12-DAC552F3742AQ28575457-4D5F6D34-BCFD-4021-8070-F0548BC90CC4Q30848657-E8696B6A-9FC6-4A60-9AD1-EA012A8F17B3Q33220980-A6480A96-061E-4086-9E5A-58D669E530E4Q33579559-F36BAEF6-BF98-4BE8-A0A8-50E5BD96F06AQ33597162-B4AD1D9A-C17F-41D2-BFF7-BE7452975E47Q33607634-8CE152B6-C310-4EED-8795-AA94C9D64F69Q33670815-B2480351-1A30-45D0-BF22-92FCA39C773DQ33713451-E2AEF30A-3C07-4BDB-A18E-A196F41FF473Q33740329-AC514B5F-4EB8-4896-8573-DF7017838F2CQ33821892-B3163664-6DB5-4B01-9B95-553E415034A9Q33823476-F5A4A458-D9E5-4698-945C-67EE79932725Q33828255-6BB9E86C-51EF-4F66-9243-BC40FB7FBDFEQ33886630-A4BE4B89-30B1-4616-A5D4-41E2D589F08BQ33893897-CAD848AD-DF20-48DC-A135-D36123E80C0FQ33973778-4485BE16-9040-4361-BBF8-B7FF01609307Q33976093-6981533B-7A95-4842-983B-0D556CE82A48Q33992531-EFCA8D51-1D9B-4796-9FB4-AE976F9E5D1DQ34065151-3EA0AB54-6D38-400D-99C9-A60C4E772783Q34074912-898F7F01-D135-4D74-8699-92758AEBE1B7Q34163110-BAC4C3A3-B90C-4852-A0AC-C8090DC305ABQ34168385-38908126-BEA5-436F-A019-19240C59C522Q34268346-4D996F6C-F238-403C-961E-4A0B02B29F83
P2860
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@en
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@nl
type
label
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@en
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@nl
prefLabel
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@en
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@nl
P2093
P1476
Efficacy and metabolic effects ...... in type II diabetes mellitus.
@en
P2093
Inzucchi SE
Shulman GI
Spollett GR
P304
P356
10.1056/NEJM199803263381303
P407
P577
1998-03-01T00:00:00Z